Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: 2-Year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Authors: Richard B. Warren, April W. Armstrong, Shinichi Imafuku, Carle Paul, Leon Kircik, Subhashis Banerjee, Elizabeth Colston, Thomas Scharnitz, Tao Wang, Bruce Strober
